Trial Profile
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed By Related or Unrelated Donor Hematopoietic Cell Transplantation For Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Rituximab (Primary) ; Ciclosporin; Mycophenolate mofetil
- Indications Chronic lymphocytic leukaemia; Graft-versus-host disease; Lymphoma; T-cell prolymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms ND
- 20 Jun 2019 Status changed from active, no longer recruiting to completed.
- 02 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Jun 2012 New source identified and integrated (Mayo Clinic).